[PDF][PDF] Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale: Policy brief

World Health Organization - 2016 - apps.who.int
BACkGROunD Primaquine is currently the only medicine for treating relapses of
Plasmodium vivax and P. ovale malaria, due to its specific activity against malaria …

Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria

K Baird - Pathogens and global health, 2015 - Taylor & Francis
Most of the tens of millions of clinical attacks caused by Plasmodium vivax each year likely
originate from dormant liver forms called hypnozoites. We do not systematically attack that …

Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countries

J Recht, EA Ashley, NJ White - PLoS neglected tropical diseases, 2018 - journals.plos.org
Primaquine is the only available antimalarial drug that kills dormant liver stages of
Plasmodium vivax and Plasmodium ovale malarias and therefore prevents their relapse …

G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests

GJ Domingo, AW Satyagraha, A Anvikar, K Baird… - 2013 - Springer
Malaria elimination will be possible only with serious attempts to address asymptomatic
infection and chronic infection by both Plasmodium falciparum and Plasmodium vivax …

A review of the current status of G6PD deficiency testing to guide radical cure treatment for vivax malaria

A Sadhewa, S Cassidy-Seyoum, S Acharya, A Devine… - Pathogens, 2023 - mdpi.com
Plasmodium vivax malaria continues to cause a significant burden of disease in the Asia-
Pacific, the Horn of Africa, and the Americas. In addition to schizontocidal treatment, the 8 …

Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency

S Kheng, S Muth, WRJ Taylor, N Tops, K Kosal… - BMC medicine, 2015 - Springer
Background Primaquine is used to prevent Plasmodium vivax relapse; however, it is not
implemented in many malaria-endemic countries, including Cambodia, for fear of …

Single low dose primaquine (0.25 mg/kg) does not cause clinically significant haemolysis in G6PD deficient subjects

G Bancone, N Chowwiwat, R Somsakchaicharoen… - PloS one, 2016 - journals.plos.org
Background Primaquine is the only drug consistently effective against mature gametocytes
of Plasmodium falciparum. The transmission blocking dose of primaquine previously …

The reality of using primaquine

KL Burgoine, G Bancone, F Nosten - Malaria journal, 2010 - Springer
Background Primaquine is currently the only medication used for radical cure of
Plasmodium vivax infection. Unfortunately, its use is not without risk. Patients with glucose-6 …

Mass primaquine treatment to eliminate vivax malaria: lessons from the past

A Kondrashin, AM Baranova, EA Ashley, J Recht… - Malaria journal, 2014 - Springer
Recent successes in malaria control have put malaria eradication back on the public health
agenda. A significant obstacle to malaria elimination in Asia is the large burden of …

G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients

S Avalos, RE Mejia, E Banegas, C Salinas, L Gutierrez… - Malaria journal, 2018 - Springer
Background The incidence of malaria in the Americas has decreased markedly in recent
years. Honduras and the other countries of Mesoamerica and the island of Hispaniola have …